3
On Friday, Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and missing the consensus of $0.15.
The company reported sales of $730.52 million, up 18% year-over-year, beating the consensus of $707.6 million.
The increase was driven by Affordable Medicines (previously Generics) revenues growing 21% due to new product launches, biosimilars, and multiple other complex products, AvKARE revenues growing 14% due to new product launches, and Specialty revenues growing 16% driven by key branded products including CREXONT.
